Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 67 entries
Sorted by: Best Match Show Resources per page
In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Frontiers in pharmacology

Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H.
PMID: 26793104
Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.

We reported evidence of bradykinin (BK) regeneration from C-terminal extended BK sequences that behave as peptidase-activated B2 receptor (B2R) agonists. Further to these in vitro studies, we carried out in vivo experiments to verify hemodynamic effects of BK analogs...

Cite
Jean M, Gera L, Charest-Morin X, et al. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016;6:306doi: 10.3389/fphar.2015.00306.
Jean, M., Gera, L., Charest-Morin, X., Marceau, F., & Bachelard, H. (2015). In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Frontiers in pharmacology, 6306. https://doi.org/10.3389/fphar.2015.00306
Jean, Mélissa, et al. "In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases." Frontiers in pharmacology vol. 6 (2015): 306. doi: https://doi.org/10.3389/fphar.2015.00306
Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015. PMID: 26793104; PMCID: PMC4709452.
Copy Download .nbib Format: NLM
Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.

Hypertension (Dallas, Tex. : 1979)

Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA.
PMID: 11208766
Hypertension. 2001 Jan;37(1):121-128. doi: 10.1161/01.hyp.37.1.121.

-The kallikrein-kininogen-kinin system is an important vasodilator and vasodepressor component of the cardiovascular system. Acting mainly through B(2) receptors, kinins may counterbalance the pressor effect of angiotensin II, salt, and mineralocorticoids plus salt. Using rats lacking the bradykinin precursors...

Cite
Rhaleb NE, Yang XP, Nanba M, et al. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension. 2001;37(1):121-128doi: 10.1161/01.hyp.37.1.121.
Rhaleb, N. E., Yang, X. P., Nanba, M., Shesely, E. G., & Carretero, O. A. (2001). Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension (Dallas, Tex. : 1979), 37(1), 121-128. https://doi.org/10.1161/01.hyp.37.1.121
Rhaleb, Nour-Eddine, et al. "Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats." Hypertension (Dallas, Tex. : 1979) vol. 37,1 (2001): 121-128. doi: https://doi.org/10.1161/01.hyp.37.1.121
Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension. 2001 Jan;37(1):121-128. doi: 10.1161/01.hyp.37.1.121. PMID: 11208766.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16845450
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(5):323-43
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(5), 323-43.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,5 (2006): 323-43.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43. PMID: 16845450.
Copy Download .nbib Format: NLM
Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism.

The World Allergy Organization journal

Riedl M.
PMID: 23282868
World Allergy Organ J. 2010 Sep;3(9):S34-8. doi: 10.1097/WOX.0b013e3181f20dbc.

Current strategies for the treatment of hereditary angioedema (HAE) include targeted inhibition or antagonism of the contact system, which is dysregulated in HAE patients by a C1 esterase inhibitor deficiency. Ecallantide, a plasma kallikrein inhibitor, and icatibant, a selective...

Cite
Riedl M. Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism. World Allergy Organ J. 2010;3(9):S34-8doi: 10.1097/WOX.0b013e3181f20dbc.
Riedl, M. (2010). Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism. The World Allergy Organization journal, 3(9), S34-8. https://doi.org/10.1097/WOX.0b013e3181f20dbc
Riedl, Marc. "Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism." The World Allergy Organization journal vol. 3,9 (2010): S34-8. doi: https://doi.org/10.1097/WOX.0b013e3181f20dbc
Riedl M. Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism. World Allergy Organ J. 2010 Sep;3(9):S34-8. doi: 10.1097/WOX.0b013e3181f20dbc. PMID: 23282868; PMCID: PMC3666151.
Copy Download .nbib Format: NLM
Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus.

Frontiers in medicine

Longhurst H.
PMID: 29594115
Front Med (Lausanne). 2018 Mar 12;4:245. doi: 10.3389/fmed.2017.00245. eCollection 2017.

Acute treatment of hereditary angioedema due to C1 inhibitor deficiency has become available in the last 10 years and has greatly improved patients' quality of life. Two plasma-derived C1 inhibitors (Berinert and Cinryze), a recombinant C1 inhibitor (Ruconest/Conestat alpha),...

Cite
Longhurst H. Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus. Front Med (Lausanne). 2018;4:245doi: 10.3389/fmed.2017.00245.
Longhurst, H. (2017). Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus. Frontiers in medicine, 4245. https://doi.org/10.3389/fmed.2017.00245
Longhurst, Hilary. "Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus." Frontiers in medicine vol. 4 (2017): 245. doi: https://doi.org/10.3389/fmed.2017.00245
Longhurst H. Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus. Front Med (Lausanne). 2018 Mar 12;4:245. doi: 10.3389/fmed.2017.00245. eCollection 2017. PMID: 29594115; PMCID: PMC5857575.
Copy Download .nbib Format: NLM
Clinical manifestations of hereditary angioedema and a systematic review of treatment options.

Laryngoscope investigative otolaryngology

Rosi-Schumacher M, Shah SJ, Craig T, Goyal N.
PMID: 34195359
Laryngoscope Investig Otolaryngol. 2021 Apr 03;6(3):394-403. doi: 10.1002/lio2.555. eCollection 2021 Jun.

OBJECTIVE: This study systematically reviews the existing literature on the management of hereditary angioedema (HAE) and provides an update on the clinical presentation and specific therapies.METHODS: A literature search of PubMed and Embase databases was conducted from start of...

Cite
Rosi-Schumacher M, Shah SJ, Craig T, et al. Clinical manifestations of hereditary angioedema and a systematic review of treatment options. Laryngoscope Investig Otolaryngol. 2021;6(3):394-403doi: 10.1002/lio2.555.
Rosi-Schumacher, M., Shah, S. J., Craig, T., & Goyal, N. (2021). Clinical manifestations of hereditary angioedema and a systematic review of treatment options. Laryngoscope investigative otolaryngology, 6(3), 394-403. https://doi.org/10.1002/lio2.555
Rosi-Schumacher, Mattie, et al. "Clinical manifestations of hereditary angioedema and a systematic review of treatment options." Laryngoscope investigative otolaryngology vol. 6,3 (2021): 394-403. doi: https://doi.org/10.1002/lio2.555
Rosi-Schumacher M, Shah SJ, Craig T, Goyal N. Clinical manifestations of hereditary angioedema and a systematic review of treatment options. Laryngoscope Investig Otolaryngol. 2021 Apr 03;6(3):394-403. doi: 10.1002/lio2.555. eCollection 2021 Jun. PMID: 34195359; PMCID: PMC8223449.
Copy Download .nbib Format: NLM
Hereditary Angioedema: A Gynecology and Obstetrics Perspective.

Cureus

Évora F, Rodolfo A.
PMID: 34976488
Cureus. 2021 Nov 24;13(11):e19861. doi: 10.7759/cureus.19861. eCollection 2021 Nov.

Hereditary angioedema is an autosomal dominant genetic disease that causes tissue edema mediated by bradykinin. The angioedema attacks have several triggers including stress, trauma, infection, and increased estrogens levels. This explains the greater incidence and clinical severity in women,...

Cite
Évora F, Rodolfo A. Hereditary Angioedema: A Gynecology and Obstetrics Perspective. Cureus. 2021;13(11):e19861doi: 10.7759/cureus.19861.
Évora, F., & Rodolfo, A. (2021). Hereditary Angioedema: A Gynecology and Obstetrics Perspective. Cureus, 13(11), e19861. https://doi.org/10.7759/cureus.19861
Évora, Francisco, and Rodolfo, Ana. "Hereditary Angioedema: A Gynecology and Obstetrics Perspective." Cureus vol. 13,11 (2021): e19861. doi: https://doi.org/10.7759/cureus.19861
Évora F, Rodolfo A. Hereditary Angioedema: A Gynecology and Obstetrics Perspective. Cureus. 2021 Nov 24;13(11):e19861. doi: 10.7759/cureus.19861. eCollection 2021 Nov. PMID: 34976488; PMCID: PMC8712210.
Copy Download .nbib Format: NLM
Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan.

Cureus

Sabeen Ahmed A, Fayyaz S.
PMID: 32923264
Cureus. 2020 Aug 11;12(8):e9669. doi: 10.7759/cureus.9669.

Hereditary angioedema (HAE) due to a C1-esterase inhibitor(C1-INH) deficiency is a rare and potentially life-threatening disorder. It is characterized by an episodic and self-limiting increase in vascular permeability. The condition manifests itself as recurrent attacks of swelling in any...

Cite
Sabeen Ahmed A, Fayyaz S. Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan. Cureus. 2020;12(8):e9669doi: 10.7759/cureus.9669.
Sabeen Ahmed, A., & Fayyaz, S. (2020). Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan. Cureus, 12(8), e9669. https://doi.org/10.7759/cureus.9669
Sabeen Ahmed, Amber, and Fayyaz, Sidra. "Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan." Cureus vol. 12,8 (2020): e9669. doi: https://doi.org/10.7759/cureus.9669
Sabeen Ahmed A, Fayyaz S. Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan. Cureus. 2020 Aug 11;12(8):e9669. doi: 10.7759/cureus.9669. PMID: 32923264; PMCID: PMC7485914.
Copy Download .nbib Format: NLM
Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA).

Postepy dermatologii i alergologii

Nowicki RJ, Grubska-Suchanek E, Porêbski G, Kowalski ML, Jahnz-Różyk K, Matuszewski T, Rudnicka L, Kulus M, Barañska-Rybak W, Czajkowski R, Doniec Z, Kowalewski C, Krêcisz B, Lange M, Narbutt J, Olszewska M, Sokołowska-Wojdyło M, Szczerkowska-Dobosz A, Śpiewak R, Trzeciak M, Wilkowska A.
PMID: 32994763
Postepy Dermatol Alergol. 2020 Aug;37(4):445-451. doi: 10.5114/ada.2020.98226. Epub 2020 Sep 02.

Angioedema is a non-inflammatory oedema of the subcutaneous tissue and/or mucosal membranes. It most commonly coexists with urticaria wheals and is considered to be a deep form of urticaria. Less commonly, it occurs in isolation and can take two...

Cite
Nowicki RJ, Grubska-Suchanek E, Porêbski G, et al. Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA). Postepy Dermatol Alergol. 2020;37(4):445-451doi: 10.5114/ada.2020.98226.
Nowicki, R. J., Grubska-Suchanek, E., Porêbski, G., Kowalski, M. L., Jahnz-Różyk, K., Matuszewski, T., Rudnicka, L., Kulus, M., Barañska-Rybak, W., Czajkowski, R., Doniec, Z., Kowalewski, C., Krêcisz, B., Lange, M., Narbutt, J., Olszewska, M., Sokołowska-Wojdyło, M., Szczerkowska-Dobosz, A., Śpiewak, R., Trzeciak, M., & Wilkowska, A. (2020). Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA). Postepy dermatologii i alergologii, 37(4), 445-451. https://doi.org/10.5114/ada.2020.98226
Nowicki, Roman J, et al. "Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA)." Postepy dermatologii i alergologii vol. 37,4 (2020): 445-451. doi: https://doi.org/10.5114/ada.2020.98226
Nowicki RJ, Grubska-Suchanek E, Porêbski G, Kowalski ML, Jahnz-Różyk K, Matuszewski T, Rudnicka L, Kulus M, Barañska-Rybak W, Czajkowski R, Doniec Z, Kowalewski C, Krêcisz B, Lange M, Narbutt J, Olszewska M, Sokołowska-Wojdyło M, Szczerkowska-Dobosz A, Śpiewak R, Trzeciak M, Wilkowska A. Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA). Postepy Dermatol Alergol. 2020 Aug;37(4):445-451. doi: 10.5114/ada.2020.98226. Epub 2020 Sep 02. PMID: 32994763; PMCID: PMC7507159.
Copy Download .nbib Format: NLM
Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells.

Hypertension (Dallas, Tex. : 1979)

Heitsch H, Brovkovych S, Malinski T, Wiemer G.
PMID: 11208759
Hypertension. 2001 Jan;37(1):72-76. doi: 10.1161/01.hyp.37.1.72.

-The stimulation of endothelium-dependent NO release by angiotensin-(1-7) [Ang-(1-7)] has been indirectly shown in terms of vasodilation, which was diminished by NO synthase inhibition or removal of the endothelium. However, direct measurement of endothelium-derived NO has not been analyzed....

Cite
Heitsch H, Brovkovych S, Malinski T, et al. Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension. 2001;37(1):72-76doi: 10.1161/01.hyp.37.1.72.
Heitsch, H., Brovkovych, S., Malinski, T., & Wiemer, G. (2001). Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension (Dallas, Tex. : 1979), 37(1), 72-76. https://doi.org/10.1161/01.hyp.37.1.72
Heitsch, Holger, et al. "Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells." Hypertension (Dallas, Tex. : 1979) vol. 37,1 (2001): 72-76. doi: https://doi.org/10.1161/01.hyp.37.1.72
Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension. 2001 Jan;37(1):72-76. doi: 10.1161/01.hyp.37.1.72. PMID: 11208759.
Copy Download .nbib Format: NLM
[No title available]

Frontiers in pharmacology

Lesage A, Gibson C, Marceau F, Ambrosi HD, Saupe J, Katzer W, Loenders B, Charest-Morin X, Knolle J.
PMID: 32636746
Front Pharmacol. 2020 Jun 19;11:916. doi: 10.3389/fphar.2020.00916. eCollection 2020.

We here report the discovery and early characterization of Compound 3, a representative of a novel class of small molecule bradykinin (BK) B

Cite
Lesage A, Gibson C, Marceau F, et al. . Front Pharmacol. 2020;11:916doi: 10.3389/fphar.2020.00916.
Lesage, A., Gibson, C., Marceau, F., Ambrosi, H. D., Saupe, J., Katzer, W., Loenders, B., Charest-Morin, X., & Knolle, J. (2020). . Frontiers in pharmacology, 11916. https://doi.org/10.3389/fphar.2020.00916
Lesage, Anne, et al. "." Frontiers in pharmacology vol. 11 (2020): 916. doi: https://doi.org/10.3389/fphar.2020.00916
Lesage A, Gibson C, Marceau F, Ambrosi HD, Saupe J, Katzer W, Loenders B, Charest-Morin X, Knolle J. . Front Pharmacol. 2020 Jun 19;11:916. doi: 10.3389/fphar.2020.00916. eCollection 2020. PMID: 32636746; PMCID: PMC7316994.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 67 entries